Loading clinical trials...
Loading clinical trials...
A Phase 3 Safety and Efficacy Trial of FLT201 Gene Therapy in Patients With Gaucher Disease Type 1
Conditions
Interventions
FLT201
Locations
3
United States
Duke University Medical Center
Durham, North Carolina, United States
University of Texas Southwestern
Dallas, Texas, United States
Lysosomal Rare Disorders Research and Treatment Center
Fairfax, Virginia, United States
Start Date
April 7, 2026
Primary Completion Date
July 1, 2028
Completion Date
October 1, 2032
Last Updated
April 21, 2026
Lead Sponsor
Spur Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions